AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04393428 — intervention group
Intervention type: OTHER
Intervention: [TIMP-2]*[IGFBP-7]
Description: \[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Study NCT05951842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anesthetic method
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
Study NCT05951842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anesthetic method
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
Study NCT03946410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
Study NCT03946410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
Study NCT00263562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid arm
Description: Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
Study NCT00263562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
Study NCT00069329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: daily injection of subcutaneous injection
Study NCT02707744 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02811978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
Study NCT02811978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
Study NCT01526369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT01526369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01526369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01526369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01526369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT03522168 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
Study NCT03522168 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Description: Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
Study NCT02650349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Study NCT04613869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Esketamine hydrochloride+Hydromorphone
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
Study NCT04613869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Esketamine hydrochloride+Hydromorphone
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
Study NCT04613869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: No esketamine added
Study NCT00986232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
Study NCT00986232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A single 0.5 mL subcutaneous injection at Day 0
Study NCT00986232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: PUVV
Description: A single 0.5 mL subcutaneous injection at Day 0
Study NCT02184247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anhydrous theophylline, 350 mg
Study NCT02184247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anhydrous theophylline, 300 mg
Study NCT03561740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: additional metronomic chemotherapy of capecitabine
Study NCT03608085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Heart failure MTM training
Description: The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;
Study NCT03608085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Heart failure MTM intervention
Description: The baseline visit will take place >= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers.
Study NCT04693728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilient Intrinsic Self-Regulation Strategies in Extremes
Description: The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
Study NCT01721239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Followup program
Description: Standardized written information, patient photos and three followup consultations.
Study NCT02585167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operation
Description: the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
Study NCT02585167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAAFT
Description: Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
Study NCT05205395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasound
Description: Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
Study NCT03010865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate
Description: Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
Study NCT03010865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
Study NCT04280861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention
Description: Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
Study NCT02471742 — intervention group
Intervention type: PROCEDURE
Intervention: NAC-sparing mastectomy
Description: patients treated with mastectomy with conservation of nipple-areola complex
Study NCT02471742 — intervention group
Intervention type: PROCEDURE
Intervention: conventional mastectomy
Description: patients treated with mastectomy without conservation of nipple-areola complex
Study NCT00770094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Lasers
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
Study NCT00770094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser for the LASIK procedure
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
Study NCT00770094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser for LASIK
Description: WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
Study NCT00549328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib monotherapy
Study NCT03008577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in ambient operating room temperature
Study NCT00894647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream
Description: Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
Study NCT00894647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
Study NCT01913470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
Study NCT02369926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Sclerosis Functional Composite
Description: The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
Study NCT02369926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Multiple Sclerosis Functional Composite
Description: The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
Study NCT04094636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-bed cycling
Description: Patients will daily perform 30 min of supervised in-bed cycling
Study NCT04094636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise booklet
Description: Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
Study NCT03794323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet
Study NCT03794323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT00985790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: Intramuscular injection
Study NCT00985790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Intramuscular injection
Study NCT02623270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilator, V60 (Philips)
Description: The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
Study NCT02623270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Bag
Description: Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
Study NCT04680143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic erythropoietin injection
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Study NCT01528774 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
Study NCT01666314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets
Study NCT01666314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel
Description: Orteronel tablets
Study NCT01666314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets
Study NCT01666314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg
Study NCT01666314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone 5 mg
Study NCT01598220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation therapy
Description: Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient.
Study NCT01598220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: attentional task
Description: The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
Study NCT00732693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol / Norethisterone
Description: Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days
Study NCT00732693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol / Progesterone
Description: Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
Study NCT03281915 — intervention group
Intervention type: PROCEDURE
Intervention: High inguinal Varicocelectomy
Description: Semen parameters after high inguinal varicocelectomy will be collected
Study NCT03281915 — intervention group
Intervention type: PROCEDURE
Intervention: Subinguinal varicocelectomy
Description: Semen parameters after subinguinal Varicocelectomy will be collected
Study NCT03191201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Study NCT03191201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Study NCT03896360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food order behavioral intervention plus standard care
Description: Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
Study NCT03896360 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
Study NCT00997815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Concentration at 2 units per 0.1 of normal saline dilution
Study NCT00997815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: Using normal saline 2.5 ml injected in control side
Study NCT03908008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT03908008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT03908008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MT10107 (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT03908008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10107 (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT03418974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
Study NCT03418974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
Study NCT03418974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
Study NCT02002208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Oral CRTH2 antagonist
Study NCT02002208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OC000459
Description: Oral CRTH2 antagonist
Study NCT00890721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: During the operation, 30cc of SKY0402 are injected into the wound.
Study NCT00890721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the hemorrhoidectomy, 30cc Placebo injected into the wound.
Study NCT02003027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT injection